Immune checkpoint inhibitors in NSCLC

Area of Science:

• Oncology
• Immunology

Background:

• Lung cancer remains a leading cause of cancer mortality globally.
• Current treatments like chemotherapy and tyrosine kinase inhibitors offer limited survival benefits for metastatic disease.

Purpose of the Study:

• To review the emerging role of immune checkpoint inhibitors (ICIs) in lung cancer treatment.
• To discuss the efficacy, safety, and potential biomarkers for ICIs in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

Main Methods:

• Review of phase I trial data for ICIs targeting PD-1/PD-L1 and CTLA-4.
• Analysis of objective response rates and toxicity profiles of anti-PD-1/PD-L1 therapies.

Main Results:

• Anti-PD-1/PD-L1 therapies as single agents in refractory patients yield 15%-25% objective response rates, with many responses durable for over a year.
• ICI toxicity profiles are generally more favorable than traditional cytotoxic chemotherapy.
• Biomarkers such as tumor PD-L1 expression and tumor-infiltrating lymphocytes show potential for guiding treatment selection.

Conclusions:

• Immune checkpoint inhibitors represent a promising new therapeutic avenue for lung cancer patients.
• Further investigation is required to determine optimal patient populations, treatment timing, and the role of combination therapies with existing treatments.